Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing oxygen-containing organic compound
Reexamination Certificate
2000-12-08
2002-09-17
Nashed, Nashaat T. (Department: 1652)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing oxygen-containing organic compound
C435S041000, C435S194000, C435S325000, C435S410000, C435S252300, C435S252330, C435S254110, C435S320100, C536S023100, C536S023200, C536S023500
Reexamination Certificate
active
06451568
ABSTRACT:
The present invention relates generally to the field of lipid biochemistry. More specifically, the present invention relates to the cloning of human choline/ethanolaminephosphotransferases.
BACKGROUND OF THE INVENTION
Cholinephosphotransferase catalyzes the final step in the synthesis of PtdCho through the Kennedy (CDP-choline) pathway via the transfer of a phosphocholine moiety from CDP-choline to diacylglycerol with the release of CMP and the formation of PtdCho (Vance, 1996 in
Biochemistry of Lipids, Lipoproteins and Membranes
, Vance, D E and Vance, J E, Elsevier: Amsterdam, pp 153-182; Kennedy and Weiss, 1956
, J Biol Chem
222:193-214; Weiss et al, 1958
, J Biol Chem
231:53-64; McMaster and Bell, 1997
, Biochim Biophys Acta
1348:100-110; Hjelmstad and Bell, 1991
, J Biol Chem
266:4357-4365; McMaster and Bell, 1994
, J Biol Chem
269:28010-28016; and Cornell, 1989 in
Phosphatidylcholine Metabolism
, Vance, D E, Boca Raton: Fla., pp. 47-64). The fatty acyl composition of the diacylglycerol molecule utilized by cholinephosphotransferase determines the fatty acyl array for de novo synthesized PtdCho. In addition, the intracellular location of cholinephosphotransferase identifies the site of de novo PtdCho synthesis for subsequent transfer to other organelles, or assembly with proteins and other lipids for secretion during the synthesis of lung surfactant, lipoproteins, and bile (Jobe, 1993
, N Engl J Med
328:861-868; Steinberg, 1997
, J Biol Chem
272 2Q963-20966; Ruetz and Gros, 1994
, Cell
77:1071-1081).
Properties of cholinephosphotransferase activities present in membrane preparations have identified an activity capable of de novo synthesis of the PtdCho structural analogues, platelet activating factor (PAF), a major mediator of inflammatory processes, as well as PAF precursor (Snyder, 1997
, Biochim Biophys Acta
1348:111-116; Leslie, 1997
, J Biol Chem
272:16709-16712; Venable et al, 1993
, J Lipid Res
34:691-702). However, the biological and biochemical roles of a de novo synthesized PAF pathway, and indeed the roles of the various proposed isoforms of cholinephosphotransferase in the regulation of the partitioning of lipid biosynthetic pathways, have yet to be determined as a mammalian cholinephosphotransferase has not been cloned or purified.
Genetic approaches led to the isolation of two genes encoding cholinephosphotransferase activities from the yeast
Saccharomyces cerevisiae
. The yeast CPT1 gene product encodes a cholinephosphotransferase (McMaster and Bell, 1994; Hjelmstad and Beg, 1990
, J Biol Chem
265:1755-1764: Hjelmstad and Bell, 1987
, J Biol Chem
262:3909-3917) specific for the synthesis of PtdCho in vitro and in vivo, while the EPT1 gene product codes for a dual specificity choline/ethanolaminephosphotransferase capable of synthesizing PtdCho and phosphatidylethanolamine (PtdEtn) in vitro, but which synthesizes primarily PtdEtn in vivo (McMaster and Bell, 1994; Hjelmstad and Bell, 1991
, J Biol Chem
266:5094-5103). Analysis of chimeric CPT1/EPT1 enzymes (McMaster and Bell, 1994; Hjelmstad and Bell, 1991; Hjelmstad and Bell, 1988
. J Biol Chem
263:19748-19757) mapped the active site domain, and site-directed mutagenesis identified a diagnostic catalytic motif (Hjelmstad et al, 1994
, J Biol Chem
269:2009521002). It was hypothesized that active site residues would be conserved between Genera. This rationale was used as a basis to isolate human choline/ethanolaminephosphotransferase cDNAs (hCEPT1 and hCEPT2) for subsequent expression and characterization.
SUMMARY OF THE INVENTION
According to a first aspect of the invention, there is provided an isolated native, cloned, recombinant or synthetic DNA sequence encoding hCEPT1 protein comprising nucleotides 497-2051 of SEQ ID NO,: or sub-fragments thereof.
According to a second aspect of the invention, there is provided an hCEPT1 protein having an amino acid sequence substantially as shown in SEQ ID NO:2.
According to a third aspect of the invention, there is provided a DNA molecule encoding hCEPT1 protein, said DNA deduced from the amino acid sequence of SEQ ID NO2.
According to a fourth aspect of the invention, there is provided an isolated native, cloned, recombinant or synthetic DNA sequence encoding hCEPT2 protein comprising nucleotides 1-881 of SEQ ID NO:3 or sub-fragments thereof.
According to a fifth aspect of the invention, there is provided hCEPT2 protein having an amino acid sequence substantially as shown in SEQ ID NO:4.
According to a sixth aspect of the invention, there is provided a DNA molecule encoding hCEPT1 protein, said DNA deduced from the amino acid sequence according to SEQ ID NO:4.
According to a seventh aspect of the invention, there is provided a recombinant expression system, capable, when transformed into a host cell, of expressing a DNA sequence encoding hCEPT1 (SEQ ID NO:2) or hCEPT2 (SEQ ID NO:3) which system comprises control sequences effective in said host cell operably linked to said DNA sequence.
According to an eighth aspect of the invention, there is provided a host cell transformed with the expression system described above.
The host cell may be selected from the group consisting of: a plant cell; a yeast cell; a bacterial cell; and a mammalian cell.
According to a ninth aspect of the invention, there is provided mutant hCEPT1 protein having an amino acid sequence substantially as shown in
FIG. 2A
(SEQ ID NO:2) and having a missense mutation at glycine 156.
According to a tenth aspect of the invention, there is provided a DNA molecule encoding mutant hCEPT1 protein, said DNA deduced from the amino acid sequence described above.
According to an eleventh aspect of the invention, there is provided mutant hCEPT2 protein having an amino acid sequence substantially as shown in
FIG. 2B
(SEQ ID NO:4) and having a missense mutation at glycine 156.
According to a twelfth aspect of the invention, there is provided a DNA molecule encoding mutant hCEPT2 protein, said DNA deduced from the amino acid sequence described above.
According to a thirteenth aspect of the invention, there are provided antibodies directed against hCEPT, said hCEPT selected from the group consisting of: hCEPT1 (SEQ ID NO:2); hCEPT2 (SEQ ID NO:4); mutant hCEPT1 protein having an amino acid sequence substantially as shown in SEQ ID NO:2 and having a missense mutation at glycine 156; mutant hCEPT2 protein having an amino acid sequence substantially as shown in SEQ ID NO:4 and having a missense mutation at glycine 156; and immunoreactive fragments thereof.
The antibodies described above may be used to identify proteins related to hCEPT1 and hCEPT2 or for diagnostic use.
According to a fourteenth aspect of the invention, there is provided a method of synthesizing lipids containing a given fatty acid composition comprising:
providing hCEPT protein, selected from the group consisting of: hCEPT1 (SEQ ID NO:2); hCEPT2 (SEQ ID NO:4); mutant hCEPT1 protein having an amino acid sequence substantially as shown in SEQ ID NO:2 and having a missense mutation at glycine 156; mutant hCEPT2 protein having an amino acid sequence substantially as shown in SEQ ID NO:4 and having a missense mutation at glycine 156; and combinations thereof;
providing substrates required for lipid biosynthesis;
combining the hCEPT protein and the substrates;
incubating the hCEPT protein and the substrates under conditions promoting lipid biosynthesis; and
harvesting the lipids.
According to a fifteenth aspect of the invention, there is provided lipids prepared according to the above-described method.
The lipids may be used as a food additive.
According to a sixteenth aspect of the invention, there is provided a method of assaying a compound for modulation of lipid metabolism comprising:
providing hCEPT protein, selected from the group consisting of: hCEPT1 (SEQ ID NO:2); hCEPT2 (SEQ ID NO:4); mutant hCEPT1 protein having an amino acid sequence substantially as shown in SEQ ID NO:2 and having a missense mutation at glycine 156; mutant hCEPT2 protein having an amino acid sequence substantially as shown in SEQ ID NO:4 and having a mis
Henneberry Anette
McMaster Christopher
Battison Adrian D.
Dalhousie University
Dupuis Ryan W.
Nashed Nashaat T.
Williams Michael R.
LandOfFree
Cloning of human choline ethanolaminephospho transferases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning of human choline ethanolaminephospho transferases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning of human choline ethanolaminephospho transferases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2843941